Kyowa Kirin adopts AI platform Benchling to boost drug research efficiency in Japan.

Kyowa Kirin, a global specialty pharmaceutical company, is implementing the AI platform Benchling at its Tokyo and Fuji Research Parks to enhance research and development. Supported by Cognizant, Benchling will automate workflows, integrate data management, and enable AI-driven experiment planning and molecular design. This integration aims to accelerate drug discovery cycles, improve data accuracy, and boost researcher productivity, helping Kyowa Kirin address complex medical challenges and expand its innovative pipeline. The collaboration also focuses on cost efficiency and flexible expense management for sustainable growth.